Daxor Corp Dossier - Source-backed chat

Daxor Corp

DXRNASDAQ

SectorHealth Care

IndustryHealth Care Equipment

Beta (adjusted)0.51

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $10.98Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $64.1M

Shares Outstanding 5.8M diluted

Last ex-dividend5 Jan 2018

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Daxor Corporation is undergoing a major strategic transformation, transitioning from a closed-end investment fund profile to a pure-play medical technology operating company. This shift is supported by the sale of its remaining investment portfolio in December 2025 and its planned transition to the Securities Exchange Act of 1934 reporting framework. The core investment thesis rests on Daxor's near-monopoly in direct, FDA-cleared blood volume measurement technology (BVA-100 and its next-generation portable analyzer cleared in August 2025). With a highly scalable 'razor-and-blades' recurring revenue model, a strong regulatory moat, and a newly fortified balance sheet following a $9 million capital raise in January 2026, Daxor is well-positioned to accelerate commercial adoption in high-value clinical settings like heart failure and critical care.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets2 analysts · as of 18 Aug 2026

Low · most bearish analyst$22.00

Mean target$22.50

High · most bullish analyst$23.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$12.0020%

Commercial adoption of BVA technology remains slow due to clinical inertia and reliance on traditional surrogate markers (e.g., blood pressure, urine output). The $9 million capital is consumed by high R&D and sales expansion costs without generating proportional recurring kit revenue, leading to further dilutive capital raises and a depressed valuation.

Base CaseCentral scenario

$22.5050%

Matches the consensus mean

Steady commercial expansion of the BVA technology with operating revenue growing at 30-45% annually. The transition to Exchange Act reporting is completed smoothly, improving investor visibility and attracting institutional coverage. The company utilizes its $9 million cash injection to expand its sales force, gradually narrowing its operating loss and moving toward break-even.

Bull CaseUpside scenario

$25.0030%

Rapid commercial adoption of the next-generation portable Blood Volume Analyzer, accelerated by the ezBVA Lab service model which eliminates capital expenditure hurdles for hospitals. Operating revenues surge past consensus estimates, driven by high-volume clinical accounts and military contracts, leading to rapid operating profitability and a significant valuation re-rating as a high-growth medical diagnostics pure-play.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong regulatory moat with FDA 510(k) clearance for both the BVA-100 and the next-generation rapid, portable analyzer developed with the Department of Defense.
Highly attractive 'razor-and-blades' business model with high-margin, recurring revenue from single-use diagnostic kits.
Strategic realignment to a 100% operating focus, eliminating the complex investment fund structure and transitioning to standard Exchange Act reporting.
Fortified balance sheet with $9 million in gross proceeds from the January 2026 registered direct offering to fund commercialization.

Key Investment Risks

Clinical inertia and resistance from physicians accustomed to using traditional, less accurate surrogate markers for fluid management.
Small commercial footprint and historically low market penetration, requiring significant sales and marketing execution to scale.
Concentration risk associated with a single core product line (BVA technology).

Thesis Invalidation Triggers

Failure to complete the transition to the Securities Exchange Act of 1934 reporting framework.
A flatlining or decline in operating division revenue growth, indicating failure of the commercial sales team expansion.
Significant cash burn exceeding the newly raised capital without a clear path to operating break-even.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.